ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, resistance is frequently driven by BCR::ABL1-independent mechanisms that sustain the proliferation and survival of CML cells regardless of BCR::ABL1 inhibition, finally resulting in disease relapse and eventually progression (1–3).